148130
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.88823721
- umap2_2d
- -0.164996823
- umap1_3d
- 1.090025774
- umap2_3d
- 2.915517099
- umap3_3d
- -0.430188189
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.480
- OXIDATIVE_PHOSPHORYLATION+0.430
- MTORC1_SIGNALING+0.410
- ADIPOGENESIS+0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- FATTY_ACID_METABOLISM+0.320
- MYC_TARGETS_V1+0.320
- UV_RESPONSE_UP+0.320
- BILE_ACID_METABOLISM+0.290
- DNA_REPAIR+0.280
Top 10 suppressed
- UV_RESPONSE_DN-0.310
- TGF_BETA_SIGNALING-0.300
- MITOTIC_SPINDLE-0.290
- ANGIOGENESIS-0.280
- IL6_JAK_STAT3_SIGNALING-0.260
- KRAS_SIGNALING_UP-0.220
- WNT_BETA_CATENIN_SIGNALING-0.210
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- TNFA_SIGNALING_VIA_NFKB-0.200
- G2M_CHECKPOINT-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AD9F-TTM3-A-1-1-R-A542-39 | — | C | 0.815 |
| 2 | SRR8518248 | — | E | 0.813 |
| 3 | TCGA-AN-A0FL-01A-11R-A034-07 | — | E | 0.797 |
| 4 | SRR4296070 | — | cohortA1 | 0.781 |
| 5 | 2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd | — | — | 0.780 |
| 6 | SRR8518413 | — | F | 0.774 |
| 7 | TCGA-37-4133-01A-01R-1100-07 | — | cohortSQ1 | 0.773 |
| 8 | AUR-AD9I-TTM3-A-1-1-R-A542-39 | — | C | 0.772 |
| 9 | ee24b470-4509-4687-a91e-6d2b967336b9 | — | — | 0.768 |
| 10 | SRR9879284 | — | cohortA1 | 0.768 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.480 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.320 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |